Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ:

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Signs Exclusive Partnership to Expand Blood Lead Testing in China

CINCINNATI, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ) today announced that its Magellan Diagnostics business unit has signed an exclusive distribution agreement with MedCaptain Medical Technology Co., Ltd. (MedCaptain, www.medcaptain.com/en/ ), a leading innovator in the fields of infusion management, in-vitro diagnostics, and rehabilitation care in the Chinese market.  Magellan Diagnostics’ LeadCare ® II blood lead testing system is the only FDA and CFDA cleared, rapid and portable system capable of providing a quantitative blood lead result in just three minutes.  LeadCare II is used in thousands of pediatric and primary care settings in the United States to help doctors diagnose lead exposure quickly and easily. 

Based on Guidelines from the National Health and Family Planning Commission of China, testing for blood lead levels is a priority for monitoring heavy metal poisoning of children and adults considered at high risk. Lead is a well-known neurotoxin that can cause deficits in fertility, fetal growth, intellectual development, learning capabilities and behavior.  Often the only way to know if an individual has been exposed to lead is to conduct a blood lead test.

The need for blood lead testing is widespread across the globe, especially in areas like China where battery manufacturing/recycling, e-waste, mining and smelting industries are common. The prevalence of lead exposure varies across China, yet is believed to be 9% to 25% of the population.  Having access to portable, accurate, easy to use testing will provide clinicians greater ability to take action, reducing the impact of lead exposure on their patients.

Discussing this agreement, Amy Winslow, President and CEO of Magellan Diagnostics noted, “Our new relationship with MedCaptain is an early indicator of expected synergies between Meridian and Magellan. Following LeadCare II’s approval by the China Food and Drug Administration (CFDA) in August, Meridian’s Asia Pacific team was able to quickly identify a motivated and knowledgeable distribution partner. Together with MedCaptain, Meridian and Magellan will focus on growth in a geography where lead exposure is a significant health risk.” 

Lourdes Weltzien, President of Meridian Asia Pacific, who will oversee the partnership, commented, “We are excited about our exclusive relationship with the capable MedCaptain team, which will drive our expansion in China.  Environmental pollutants in the air, food and water continue to affect children in China.  We are looking forward to having a positive impact with a device that can be used anywhere and provide answers in three minutes.  We will focus on creating awareness about the dangers of lead exposure and how to prevent it so that the children of China can reach their full potential.”

Distribution activities with MedCaptain will begin in January 2017. Partnering with Meridian Bioscience and Magellan Diagnostics, MedCaptain will invest in educating Chinese physicians and consumers about the risks and management of lead poisoning through a series of seminars and academic conferences. 

About Magellan Diagnostics, Inc.   Magellan Diagnostics is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. A business unit of Meridian Bioscience, Inc., Magellan is headquartered outside Boston in Billerica, Massachusetts, and is dedicated to offering high-quality, reliable products that help identify children and adults at risk of harm due to lead exposure.  We are committed to educating clinicians, policy makers, payers, families and communities about the permanent health damage caused by lead and how to detect and address lead exposure.  For more information, visit www.magellandx.com .

About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com .

FORWARD-LOOKING STATEMENTS The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements.  Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context.  All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements.  Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made.  Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance.  Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.  These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:

Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products.  While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property.  Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results.  Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution.  Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results.  Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process.  The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict.  One of Meridian’s growth strategies is the acquisition of companies and product lines.  There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations.  There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives.  Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care Education and Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations.  Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues.  In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.

Contact: John A. Kraeutler Chairman, Chief Executive Officer Meridian Bioscience, Inc. Phone:  513.271.3700 Email: mbi@meridianbioscience.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 332

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 117

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 238

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 46

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 344

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Ericsson Completes Major Buyback in November Burst

Updated Category News Views 22

Ericsson's Aggressive Share Repurchase Strategy Ericsson's share buyback spree might not be the first rodeo for seasoned investors out there, but their recent grab between November 9th and 13th surely made a few heads turn. The telecom giant snatched up a neat pile of 500,000 of its own Class B shares, maintaining the steady tick of their ambitious buyback program. It's...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 15

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Willis Towers Watson's P/E Ratio Dynamics

Updated Category News Views 190

Current Stock Overview In today's market, Willis Towers Watson Inc. stock is priced at $325.59, reflecting a slight increase of 0.02%. Over the past month, the stock has risen by 5.11% and has shown a notable yearly increase of 17.73%. Such performance has led to optimism among long-term shareholders, although many are considering the price-to-earnings (P/E) ratio as a...

Continue Reading
Sterling Infrastructure to Engage Investors at Key Conferences

Updated Category News Views 79

Sterling Infrastructure to Engage Investors at Key Conferences Sterling Infrastructure, Inc. (NASDAQ: STRL) is making strides in connecting with investors by participating in several upcoming investor conferences. These events present a fantastic opportunity for the company's management to share insights and updates regarding their ongoing projects and strategic...

Continue Reading
Rivian's $5 Billion Factory Plans and Market Dynamics in EV

Updated Category News Views 224

Exciting Developments in the EV Industry The electric vehicle (EV) space has witnessed some thrilling changes recently. Major companies like Rivian, Tesla, and BYD are at the forefront of this industry evolution. This article will recap some standout events that have kept the tech world buzzing. Rivian's Ambitious Factory Plans Construction Begins on a $5 Billion Facility...

Continue Reading
Berry Global Group Secures $800 Million in Senior Notes

Updated Category News Views 273

Berry Global Group's Strategic $800 Million Notes Issuance Berry Global Group, Inc. (NYSE: BERY) has taken a significant step in bolstering its financial structure with the announcement of the issuance of $800 million in senior secured notes due in 2031. The notes, which carry an attractive interest rate of 7.250% per annum, reflect the company's ambition and strategic...

Continue Reading
AdaptHealth Corp. Welcomes Russell Schuster as CCO for Growth

Updated Category News Views 108

Russell Schuster Joins AdaptHealth as Chief Commercial Officer AdaptHealth Corp. (NASDAQ: AHCO), a prominent provider of patient-centered healthcare-at-home solutions, has made a significant addition to its leadership team by appointing Russell Schuster as Chief Commercial Officer. His role is effective immediately and brings a wealth of expertise aimed at enhancing the...

Continue Reading